Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics

Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug development that target the causal CFTR directly result in lung function improvement, but variability in response is demanding better prediction of outcomes to improve management decisions. The genetic modifie...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Hum Mol Genet
Auteurs principaux: Strug, Lisa J., Gonska, Tanja, He, Gengming, Keenan, Katherine, Ip, Wan, Boëlle, Pierre-Yves, Lin, Fan, Panjwani, Naim, Gong, Jiafen, Li, Weili, Soave, David, Xiao, Bowei, Tullis, Elizabeth, Rabin, Harvey, Parkins, Michael D., Price, April, Zuberbuhler, Peter C., Corvol, Harriet, Ratjen, Felix, Sun, Lei, Bear, Christine E., Rommens, Johanna M.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2016
Sujets:
Association Studies Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5886039/
https://ncbi.nlm.nih.gov/pubmed/28171547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/hmg/ddw290
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires